News & Updates
Filter by Specialty:

UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
In the treatment and prevention of recurrent yeast infection or vulvovaginal candidiasis, oteseconazole performs similarly to standard-of-care fluconazole but better as compared with placebo, as shown in the results of the phase III ultraviolet study.
UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
26 Jul 2022
20-µg hep B vaccine can prevent vertical transmission
Using a 20-µg dose to vaccinate children born to mothers with detectable levels of hepatitis B virus surface antigen (HBsAg) appears to avert vertical transmission, reports a recent China study.
20-µg hep B vaccine can prevent vertical transmission
23 Jul 2022
Pre-eclampsia ups risk of nonsyndromic orofacial clefts
Only pre-eclampsia, among other hypertensive disorders of pregnancy, contributes to a higher risk of nonsyndromic orofacial clefts (NSOFCs) and its subtypes, a study has found.
Pre-eclampsia ups risk of nonsyndromic orofacial clefts
21 Jul 2022
Women hospitalized with COVID-19 suffer from menstrual changes, worse mental health
COVID-19 appears to alter the menstrual cycle and impair mental health in women hospitalized for the disease, a recent study has found.
Women hospitalized with COVID-19 suffer from menstrual changes, worse mental health
21 Jul 2022
Weekly dose-dense CT does not confer survival benefit for ovarian cancer patients
In the final analysis of the phase III ICON8* study, a weekly dose-dense chemotherapy (CT) regimen comprising paclitaxel and carboplatin did not improve survival outcomes in women with epithelial ovarian cancer** compared with the standard first-line (1L) paclitaxel-carboplatin regimen given once every 3 weeks (Q3W).
Weekly dose-dense CT does not confer survival benefit for ovarian cancer patients
18 Jul 2022
Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.